BioPerfectus (SSE: 688399) is at the forefront of the molecular diagnostics industry, specializing in diagnostics for infectious diseases and women’s and children’s health. Founded in 2010, BioPerfectus has maintained a continuous focus on R&D, manufacturing, and distribution of reagents and instruments for in vitro diagnostics.
With a robust strategic plan, the company has efficiently integrated every stage—from the development and production of essential materials to the delivery of comprehensive diagnostic services.
With a diversified portfolio of more than 700 products, BioPerfectus serves a broad spectrum of medical institutions, Centers for Disease Control (CDC), and independent clinical laboratories, reaching more than 100 countries and regions.
To further strengthen its position in molecular diagnostics, BioPerfectus proactively invests in high-growth areas such as POCT (Point-of-Care Testing). The company’s strategy focuses on expanding applications, enhancing its product portfolio, and increasing its global presence.
We combine technology and care to provide accurate and reliable results.
Leading the way in molecular diagnostics, BioPerfectus has a suite of clinically validated core technologies recognized globally. This includes advanced quantitative PCR, sophisticated nucleic acid extraction solutions, and rapid testing methods.
Our commitment to excellence is evident in our production processes. Our PCR laboratories, equipped with state-of-the-art technology, are rigorously sterilized and follow the highest safety protocols, reinforcing our dedication to pioneering product development and ongoing research.
Guided by its vision, mission, and values, BioPerfectus uses precise, effective, and optimized diagnostic techniques with the aim of pioneering advanced methods for early screening and diagnosis of infectious diseases and major health challenges.
BioPerfectus for a healthier future
To be one of the leading global IVD providers
Quality, Efficiency, Impartiality, Fairness
